Denosumab

Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Denosumab and local guidelines before prescribing.

Anti-RANKL monoclonal antibody

Mechanism

RANKL monoclonal antibody inhibiting osteoclasts.

Uses

Osteoporosis, bone metastases, giant-cell tumour of bone, hypercalcaemia of malignancy (refractory).

Dosing

Side effects

Hypocalcaemia, hypophosphataemia, osteonecrosis of the jaw, atypical femoral fracture, infection; rebound vertebral fractures on stopping.

Interactions

Few drug interactions.

Contraindications and cautions

Hypocalcaemia (uncorrected)

Monitoring

Calcium (especially in renal impairment), dental health

Pregnancy and breastfeeding

Avoid; contraception during treatment

Renal and hepatic impairment

No adjustment but higher hypocalcaemia risk in CKD

Overdose and reversal

Supportive; correct calcium

Special advice

Replace calcium and vitamin D; never stop abruptly without follow-on bisphosphonate; dental review before starting.

More from the textbook: uses, cautions and other points
Where it is discussed in the book